| Optimizing the start time of statin therapy for patients with diabetes BT Denton, M Kurt, ND Shah, SC Bryant, SA Smith Medical Decision Making 29 (3), 351-367, 2009 | 120 | 2009 |
| Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence JE Mason, DA England, BT Denton, SA Smith, M Kurt, ND Shah Medical Decision Making 32 (1), 154-166, 2012 | 68 | 2012 |
| Optimally maintaining a Markovian deteriorating system with limited imperfect repairs M Kurt, JP Kharoufeh European Journal of Operational Research 205 (2), 368-380, 2010 | 67 | 2010 |
| Monotone optimal replacement policies for a Markovian deteriorating system in a controllable environment M Kurt, JP Kharoufeh Operations Research Letters 38 (4), 273-279, 2010 | 67 | 2010 |
| The structure of optimal statin initiation policies for patients with type 2 diabetes M Kurt, BT Denton, AJ Schaefer, ND Shah, SA Smith IIE Transactions on Healthcare Systems Engineering 1 (1), 49-65, 2011 | 56 | 2011 |
| From data to improved decisions: operations research in healthcare delivery M Capan, A Khojandi, BT Denton, KD Williams, T Ayer, J Chhatwal, ... Medical Decision Making 37 (8), 849-859, 2017 | 44 | 2017 |
| Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients ND Shah, J Mason, M Kurt, BT Denton, AJ Schaefer, VM Montori, ... PloS one 6 (1), e16170, 2011 | 21 | 2011 |
| What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell … SL Klijn, E Fenwick, S Kroep, K Johannesen, B Malcolm, M Kurt, C Kiff, ... Pharmacoeconomics 39, 345-356, 2021 | 18 | 2021 |
| Structured replacement policies for a Markov-modulated shock model M Kurt, LM Maillart Operations Research Letters 37 (4), 280-284, 2009 | 14 | 2009 |
| Valuing prearranged paired kidney exchanges: A stochastic game approach M Kurt, MS Roberts, AJ Schaefer, MU Unver Boston College Department of Economics, 2011 | 8 | 2011 |
| Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: a correlation meta-analysis JA Ajani, L Leung, P Singh, M Kurt, I Kim, MM Pourrahmat, S Kanters European Journal of Cancer 170, 119-130, 2022 | 6 | 2022 |
| Heterogeneity in survival with immune checkpoint inhibitors and its implications for survival extrapolations: a case study in advanced melanoma V Federico Paly, M Kurt, L Zhang, MO Butler, O Michielin, A Amadi, ... MDM Policy & Practice 7 (1), 23814683221089659, 2022 | 6 | 2022 |
| Dynamic decision models for managing the major complications of diabetes M Kurt University of Pittsburgh, 2012 | 6 | 2012 |
| Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from … S Branchoux, CL Sofeu, AF Gaudin, M Kurt, A Moshyk, A Italiano, ... ESMO open 7 (1), 100340, 2022 | 5 | 2022 |
| Comparative effectiveness of up to three lines of chemotherapy treatment plans for metastatic colorectal cancer I Toumazis, M Kurt, A Toumazi, LG Karacosta, C Kwon MDM Policy & Practice 2 (2), 2381468317729650, 2017 | 5 | 2017 |
| PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS S Kroep, C Kiff, C Kraan, M Bianco, K Johannesen, M Kurt, B Malcolm, ... Value in Health 22, S523-S524, 2019 | 4 | 2019 |
| Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial JS Weber, ... ESMO 2019, 2019 | 3 | 2019 |
| Chance-constrained programming models and approximations for general stochastic bottleneck spanning tree problems S Shen, M Kurt, J Wang INFORMS Journal on Computing 27 (2), 301-316, 2015 | 3 | 2015 |
| At what lipid ratios should a patient with type 2 diabetes initiate statins M Kurt, B Denton, AJ Schaefer, N Shah, S Smith IIE Transactions on Healthcare Engineering 1 (1), 49-65, 2009 | 3 | 2009 |
| Cost-utility of nivolumab plus ipilimumab in first-line treatment of advanced melanoma in the United States: an analysis using long-term overall survival data from checkmate 067 T Baker, H Johnson, S Kotapati, A Moshyk, M Hamilton, M Kurt, VF Paly PharmacoEconomics-Open 6 (5), 697-710, 2022 | 2 | 2022 |
